Feasibility and Limitations of Federated EHR Data for VEXAS Syndrome Ascertainment and Treatment Research (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1133; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Federated structured EHR data can support VEXAS-compatible phenotype development and burden description, but molecular confirmation, explicit diagnosis-code ascertainment, and treatment indication were not available at scale. Genetically confirmed registries, standardized VEXAS coding, structured UBA1 result capture, and validated EHR phenotypes are needed before reliable VEXAS treatment-comparative research. Multiple VEXAS-compatible ascertainment strategies were evaluated in TriNetX."
Acute Myelogenous Leukemia • Giant Cell Arteritis • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammatory Arthritis • Leukemia • Pneumonia • Pulmonary Embolism • Rare Diseases • Respiratory Diseases • Rheumatoid Arthritis • Septic Shock • Vasculitis
|
|
Maya Khasho1; Justin Lam2; Christopher Bray3
|